Tagged with ART

LatAm Adium is one of Latin America’s most expansive pharmaceutical groups, operating across 18 countries with a workforce of 7,000 employees. The organisation has unified its brand identity across the region whilst establishing world-class infrastructure and capabilities spanning oncology, rare diseases, and speciality therapeutics. The company´s strategic vision centres on positioning…

LatAm Arturo De la Rosa, Vice President for Latin America at Gilead Sciences, leverages deep regional experience to navigate healthcare challenges and opportunities across multiple countries. He oversees a dual strategy, sustaining leadership in virology while expanding Gilead’s oncology presence, aiming for it to represent a third of global revenues by…

France Created in the wake of COVID-19, the Agence de l’Innovation en Santé (AIS), part of the Secrétariat Général pour l’investissement – a Prime Minister department, has rapidly positioned itself at the heart of France’s health innovation strategy, driving progress in areas such as bioclusters, prevention, clinical research, and artificial intelligence.…

France Genopole stands as one of France’s leading bioclusters, seamlessly integrating world-class research, entrepreneurship, and industrial engagement to support over 80 companies across health and the bioeconomy. Under Gilles Trystram’s leadership, the cluster nurtures innovation from start-up creation to scaling, leveraging strategic partnerships with institutions like Université Paris-Saclay and specialised platforms…

Brazil Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active clinical trials and major launches ahead across cardiovascular-renal-metabolic, immunology, neurology and oncology, Novartis is pairing scientific innovation with new access…

China In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis worth up to USD 6 billion. These Novartis deals could come to be one of the largest ever tie-ups between…

Global As chief development officer of Moderna, Dr Melanie Ivarsson OBE spearheaded the rapid development of a COVID-19 vaccine that helped the world emerge from the pandemic. Now back in the UK and drawing on over 25 years of clinical development leadership across Lilly, Pfizer, Takeda, and Moderna, Dr Ivarsson recently…

Denmark When it comes to Denmark’s flourishing local biotech scene, the country is again clearly punching far above its weight. The EU member state has already managed to muster world-class expertise in areas like peptide chemistry and metabolic disorders, anchored by the success stories of homegrown entities that made it big…

Switzerland QIAGEN’s Sample Technologies portfolio sits at the core of the company’s mission to deliver the highest-quality products to enable valuable molecular insights to more than 500,000 customers across life sciences and clinical diagnostics. Under the leadership of Michael Scheffler, Vice President and Head of Global Sample Technologies, this portfolio continues…

Switzerland Kasha Witkos, Senior Vice President and Head of International Business at Alnylam Pharmaceuticals, shares her journey from academic researcher to global biotech leader, driven by personal family experience of chronic disease.  Witkos highlights Alnylam’s pioneering role in delivering RNA interference (RNAi) technology to patients around the world, the company’s global…

France Alexis Genin, CEO of Brain & Mind, discusses the strategic vision behind France’s first national hub for neuroscience product development. Established to overcome the fragmented landscape in neuroscience innovation, Brain & Mind unites over 40 partners across industry, research, and investment. Under Genin’s leadership, the organization has focused on closing…

USA Marwan Fathallah, President and CEO of DIA, outlines how the organisation has evolved into a neutral platform bringing together regulators, industry, and academia to navigate the most pressing issues in healthcare and life sciences. From the transformative potential of AI to the realities of drug pricing, onshoring, and global competition,…